Reappraisal of the role of radiation therapy in lymphoma treatment

Lena Specht*

*Corresponding author for this work
3 Citations (Scopus)


Radiation therapy (RT) for lymphomas has improved dramatically with modern imaging and treatment techniques, encompassing only the necessary volume with minimal doses to normal structures. Prescribed radiation doses are reduced, and fractionation schedules are under revision. With effective systemic treatment only initial macroscopic disease is irradiated. With no or less effective systemic treatment, possible microscopic disease is also included. Risks of long-term side effects of RT have diminished dramatically and should be weighed against risks from more systemic treatment or increased risk of relapse. Lymphoma patients are often elderly, they tolerate modern limited RT very well. Lymphomas refractory to systemic treatments often remain radioresponsive, and brief, mild RT may offer effective palliation. New roles for RT are emerging with immune therapies. RT for "bridging," keeping the lymphoma under control while waiting for immune therapy, is well established. Enhancement of the immune response to lymphomas, so-called "priming," is being intensively researched.

Original languageEnglish
JournalHematological Oncology
Volume41 Suppl 1
Pages (from-to)75-81
Number of pages7
Publication statusPublished - Jun 2023


  • bridging
  • high precision
  • lymphoma
  • modern techniques
  • radiation therapy


Dive into the research topics of 'Reappraisal of the role of radiation therapy in lymphoma treatment'. Together they form a unique fingerprint.

Cite this